NASDAQ: PRQRProqr Therapeutics Nv Stock
$2.13-0.06 (-2.74%)
Updated Jul 30, 2025
PRQR Price
$2.13
Fair Value Price
N/A
Market Cap
$229.42M
52 Week Low
$1.07
52 Week High
$4.62
P/E
-5.85x
P/B
2.56x
P/S
6.57x
PEG
N/A
Dividend Yield
N/A
Revenue
$22.30M
Earnings
-$32.81M
Gross Margin
100%
Operating Margin
-149.12%
Profit Margin
-153.8%
Debt to Equity
0.92
Operating Cash Flow
-$43M
Beta
0.98
Next Earnings
Jul 31, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PRQR Overview
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PRQR's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PRQR
Ranked#385 of 478
Ranked#385 of 478
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.16 | A | |
| $50.94 | A | |
| $21.01 | A |
Be the first to know about important PRQR news, forecast changes, insider trades & much more!
PRQR News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRQR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRQR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRQR is good value based on its book value relative to its share price (2.56x), compared to the US Biotechnology industry average (4.34x)
P/B vs Industry Valuation
PRQR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PRQR due diligence checks available for Premium users.
Valuation
PRQR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.85x
Industry
-199.97x
Market
32.18x
PRQR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.56x
Industry
4.34x
PRQR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRQR's financial health
Profit margin
Revenue
$5.2M
Net Income
-$11.0M
Profit Margin
-212.6%
PRQR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PRQR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$164.9M
Liabilities
$79.1M
Debt to equity
0.92
PRQR's short-term assets ($156.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRQR's short-term assets ($156.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRQR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PRQR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.8M
Investing
-$243.5k
Financing
-$543.5k
PRQR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRQR vs Biotech Stocks
Proqr Therapeutics Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.